South Korea Cardiogenic Shock Treatment Market Insight
Published: 27 June 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The market is anticipated to increase at a compound annual growth rate of 7.52% because to the aging population and rising incidence of acute myocardial infarction in South Korea.
South Korea Cardiogenic Shock Treatment Market Insights Forecasts to 2035
- The South Korea Cardiogenic Shock Treatment Market Size Was Estimated USD 18.3 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.52% from 2025 to 2035
- The South Korea Cardiogenic Shock Treatment Market Size is Expected to rise around USD 37.8 Million by 2035
Notable Insights for the South Korea Cardiogenic Shock Treatment Market
- Short-Term Circulatory Support devices lead and serve as a bridge to decision-making based on device type segmentation. The market in South Korea is dominated by intra-aortic balloon pumps and percutaneous ventricular assist devices.
- Vasopressors and inotropes continue to be the standard of care based on pharmacological therapy segmentation. Nonetheless, 84% of cardiologists anticipate using new drugs like istaroxime, which are now under research, to treat early cardiogenic shock.
- Advanced cardiac operations are reimbursed by South Korea's national health insurance system, which promotes market expansion. Germany's market for cardiogenic shock treatment, which makes up around 12% of European market for circulatory support devices.
- Due to a high rate of PCI procedures, the short-term circulatory support devices market in South Korea is estimated to be worth USD 200 million. Hospital contracts and gadget sales are major sources of income for major firms like Abbott and Getinge.
Download the eBook (ToC)
Why Buy This Report
- With comprehensive market predictions, segmentation analysis, and insights into the changing South Korean cardiogenic shock treatment landscape, it helps strategic decisions.
- The research helps stakeholders target the most profitable prospects in this life-saving therapeutic sector by identifying high-growth categories such as PVADs and new medications.
- It charts the competitive environment by evaluating major pharmaceutical and device makers and comparing them to local market trends.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Cardiogenic Shock Treatment Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Cardiogenic Shock Treatment Market
- 4TEEN4 Pharmaceuticals GmbH
- Abiomed Inc.
- Abbott Laboratories
- Getinge AB
- Teleflex Inc.
- LivaNova Plc
- Medtronic Plc
- Berlin Heart GmbH
- Bayer AG
- Novartis AG
Recent Developments:
- In March 2024, in order to enable high-risk coronary surgeries and minimally invasive mechanical circulatory support for cardiogenic shock, Abbott Laboratories increased the availability of Impella heart pump devices in South Korea.
- In May 2023, in order to encourage the use of percutaneous ventricular assist devices for acute cardiac care and the treatment of cardiogenic shock, Abiomed Inc. (Johnson & Johnson MedTech) expanded the availability of Impella heart pumps in South Korean hospitals.
Market Segmentation:
South Korea Cardiogenic Shock Treatment Market, By Product Type
- Short-Term Circulatory Support Devices (IABP, PVAD)
- Drug Therapies (Inotropes, Vasopressors)
- Long-Term Ventricular Assist Devices
South Korea Cardiogenic Shock Treatment Market, By Application
- Bridge-to-Decision
- Bridge-to-Recovery
- Acute Myocardial Infarction Management
South Korea Cardiogenic Shock Treatment Market, By End-User
- Hospitals
- Cardiac Centers
- Emergency Medical Services
Expert Views:
The cardiogenic shock therapy market in South Korea is set to see consistent growth, driven by demographic trends, an increased occurrence of myocardial infarction and advancements in mechanical circulatory support systems. Reimbursement expansion, development of critical care facilities, and innovative treatments are anticipated to boost treatment success rates. This is set to reinforce South Korea’s position as a technologically advanced market for acute cardiology care up to 2035.
Author: Govind and Krishna By Decisions Advisors and Consulting